You are here: Industry Insights > Incyte

News List

Lilly, Incyte's Olumiant fails in COVID-19 trial pharmatimes
April 13, 2021
A Phase III trial of Eli Lilly and Incyte's baricitinib has failed to meet its primary endpoint in patients hospitalised with COVID-19.
Lilly, Incyte report trial results of baricitinib in Covid-19 patients pharmaceutical-technology
April 09, 2021
Eli Lilly and Incyte have reported that the Phase III COV-BARRIER study of baricitinib failed to meet statistical significance on the primary endpoint of progression to non-invasive ventilation or invasive mechanical ventilation or death in ...
New Progress in the Hair Loss Prevention Drug Market: JAK Inhibitor Baricitinib Reaches Phase 3 Clinical Primary Endpoint PharmaSources.com
March 26, 2021
Eli Lilly and Company and Incyte jointly announced on Mar. 3, 2021 that baricitinib, an oral JAK inhibitor, met its primary endpoint in Phase 3 clinical trial for the treatment of adult patients with severe alopecia areata (AA).
Ruxolitinib (Jakafi) does not prevent complications due to COVID-19 associated cytokine storm: Study expresspharma
December 15, 2020
Incyte announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of ruxolitinib (Jakafi), a JAK1/JAK2 inhibitor, plus standard-of-care (SoC) as a treatment for patients 12 years and older with COVID-19 associated cytokine storm did ...
Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine prnewswire
December 14, 2020
Eli Lilly and Company and Incyte announced that The New England Journal of Medicine has published peer-reviewed results from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) ...
Innovent Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas prnasia
December 08, 2020
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced data from two ongoing ..
Baricitinib Receives EUA for Hospitalized Patients with COVID-19 americanpharmaceuticalreview
December 07, 2020
Eli Lilly and Company and Incyte announced the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the distribution and emergency use of baricitinib to be used in combination with remdesivir in hospitalized adult ...
FDA grants EUA for Lilly and Incyte’s baricitinib for Covid-19 treatment pharmaceutical-technology
November 23, 2020
The US Food and Drug Administration (FDA) has issued an emergency use authorisation (EUA) for Eli Lilly and Company and Incyte’s baricitinib in combination with remdesivir in hospitalised patients with Covid-19.
Lilly, Incyte tout new baricitinib data in eczema pharmatimes
November 05, 2020
Eli Lilly and Incyte showcased new data for their JAK inhibitor baricitinib in eczema at the virtual European Academy of Dermatology and Venereology (EADV) congress on Saturday.
Lilly, Incyte Release Information on Baricitinib, Remdesivir Combination for COVID-19 americanpharmaceuticalreview
October 15, 2020
Eli Lilly and Company and Incyte are sharing additional data showing baricitinib in combination with remdesivir reduced time to recovery and improved clinical outcomes for patients with COVID-19 infection compared with remdesivir.

Previous page 1 2 3 4 5 Next page